Mithridion
closedMithridion develops drugs for central nervous system disorders, with special focus on schizophrenia and Alzheimer's disease.
Employees
Enterprise value
$5—8m
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor investor investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
$1.3m | Series C | ||
| Total Funding | 000k | ||
Notes (0)
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads